Stevens-Johnson Syndrome Induced by Vandetanib

Vandetanib is a once-daily oral anticancer drug that selectively inhibits key signaling pathways in cancer by targeting vascular endothelial growth factor receptors, epidermal growth factor receptors tyrosine kinase, and rearranged during transfection-dependent tumor cell proliferation and survival....

Descripción completa

Detalles Bibliográficos
Autores principales: Yoon, Jimi, Oh, Chee Won, Kim, Chi Yeon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Dermatological Association; The Korean Society for Investigative Dermatology 2011
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3276793/
https://www.ncbi.nlm.nih.gov/pubmed/22346274
http://dx.doi.org/10.5021/ad.2011.23.S3.S343

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3276793/
https://www.ncbi.nlm.nih.gov/pubmed/22346274
http://dx.doi.org/10.5021/ad.2011.23.S3.S343

Ejemplares similares